New drug telitacicept tested for MS Flare-Ups
NCT ID NCT04625153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested telitacicept (RC18) in 8 people with relapsing-remitting multiple sclerosis. The drug aims to reduce relapses by targeting B cells. The study was terminated early, so we have limited data on safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
telitacicept (RC18)
What this could lead to
If it works, this could point toward a new treatment option for relapsing-remitting multiple sclerosis by targeting B cells to reduce flare-ups.
What could go wrong
This trial was terminated early with only 8 participants, so results are very limited. It is a phase 2 study, meaning it is still early and may not prove effective or safe in larger groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
the Third Affiliated Hospital,Sun Yat-Sen University
Guangzhou, Guangdong, China